

SUPPLEMENTAL MATERIALS

Supplemental Table 1 [online only]. Baseline demographics for patients with and without VEGF-A samples in the AVF2107, E4599, AVAiL, and AVOREN trials

Characteristic	AVF2107		E4599		AVAiL		AVOREN	
	VEGF-A sample (n = 384)	No VEGF-A sample (n = 539)	VEGF-A sample (n = 166)	No VEGF-A sample (n = 712)	VEGF-A sample (n = 882)	No VEGF-A sample (n = 161)	VEGF-A sample (n = 384)	No VEGF-A sample (n = 265)
Median age, years (range)	59 (21–86)	61 (23–88)	62 (27–78)	63 (31–88)	58 (20–83)	59 (31–83)	61 (18–81)	59 (28–82)
Sex, n (%)								
Female	164 (42.7)	205 (38.0)	67 (40.4)	333 (46.8)	316 (35.8)	62 (38.5)	115 (29.9)	77 (29.1)
Male	220 (57.3)	334 (62.0)	99 (59.6)	379 (53.2)	566 (64.2)	99 (61.5)	269 (70.1)	188 (70.9)
ECOG PS, n (%)								

0	216 (56.3)	306 (56.8)	59 (35.5)	287 (40.3)	358 (40.6)	60 (37.3)	N/A	N/A
≥1 ^a	168 (43.8)	232 (43.0)	107 (64.5)	421 (59.1)	524 (59.4)	101 (62.7)		
Missing		1 (0.2)		4 (0.6)				
Karnofsky PS, <i>n</i> (%)								
100	N/A	N/A	N/A	N/A	N/A	N/A	160 (41.7)	108 (40.8)
90							133 (34.6)	93 (35.1)
85							2 (0.5)	1 (0.4)
≤80							89 (23.2)	63 (23.8)
Metastatic sites, <i>n</i> (%)								
1	154 (40.1)	200 (37.1)	28 (16.9)	122 (17.1)	N/A	N/A	90 (23.4)	62 (23.4)
>1	230 (59.9)	339 (62.9)	133 (80.1)	553 (77.7)			292 (76.0)	202 (76.2)
Missing			5 (3.0)	37 (5.2)			2 (0.5)	1 (0.4)
Disease stage, <i>n</i> (%)								

IIIB	N/A	N/A	16 (9.6)	108 (15.2)	157 (17.8)	33 (20.5)	N/A	N/A
IV or recurrent			150 (90.4)	604 (84.8)	725 (82.2)	128 (79.5)		
Tumor measurability, <i>n</i> (%)								
No	N/A	N/A	19 (11.4)	70 (9.8)	53 (6.0)	11 (6.8)	32 (8.3)	22 (8.3)
Yes			147 (88.6)	642 (90.2)	829 (94.0)	150 (93.2)	352 (91.7)	243 (91.7)
Motzer score, <i>n</i> (%)								
Favorable	N/A	N/A	N/A	N/A	N/A	N/A	117 (30.5)	81 (30.6)
Intermediate							232 (60.4)	160 (60.4)
Poor							35 (9.1)	24 (9.1)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; N/A, not applicable; PS, performance status; VEGF-A, vascular endothelial growth factor.

^aIn AVF2107, none of the patients with VEGF-A samples had an ECOG PS >1; 4 patients (0.4%) in the total population had an ECOG PS >1. In AVAiL, none of the patients (VEGF-A sample and total population) had an ECOG PS >1. In AVAiL, none of the patients in the total population had an ECOG PS >1.


Supplemental Figure Legends

Supplemental Fig. 1 [online only]. The GEN.038 VEGF-A ELISA. Abbreviations: ELISA, enzyme-linked immunosorbent assay; MUG, 4-methylumbelliferyl β -D-galactopyranoside; VEGF-A, vascular endothelial growth factor.


Supplemental Fig. 2 [online only]. Standard curves for different VEGF-A isoforms in the GEN.038 assay. Major isoforms of VEGF-A are detected with equivalent sensitivity. Only VEGF₁₀₉, a recombinant protein, is not detected with a similar sensitivity. Abbreviations: FSU, fluorescent unit; VEGF-A, vascular endothelial growth factor.

Supplemental Fig. 3 [online only]. Correlation of baseline plasma VEGF-A levels with patient and tumor characteristics from AVOREN. (A) Motzer score. (B) Karnofsky performance status. Mean values \pm standard deviation. Abbreviation: VEGF-A, vascular endothelial growth factor.

Supplemental Fig. 1



Supplemental Fig. 2



Supplemental Fig. 3.

